{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:28:25Z","timestamp":1794083305584,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>\n            <jats:italic>MEF2D<\/jats:italic> fusions are found in a special subtype of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with poor prognosis. In this study, we conducted high-throughput drug screenings using cell line and ex vivo cell model harboring, respectively, <jats:italic>MEF2D::HNRNPUL1(MH)<\/jats:italic> and <jats:italic>MEF2D::BCL9(MB)<\/jats:italic>, the two major <jats:italic>MEF2D<\/jats:italic> fusions. We identified CUDC-907 as a highly potent dual-target inhibitor of PI3K\/HDAC, demonstrating remarkable efficacy in inducing robust lethality while maintaining selectivity for <jats:italic>MEF2D<\/jats:italic> fusion-expressing cells. CUDC-907 effectively induced apoptosis and promoted the down-regulation of pre-BCR signaling. We discovered that the hyperactivation of the PI3K-AKT signaling pathway, HDAC9, and BCL2 contributed to the sustained state of <jats:italic>MEF2D<\/jats:italic> fusion (+) BCP-ALL. Importantly, CUDC-907 exerted dual regulatory function by targeting the integrative pathways of MEF2D fusions. It suppressed the PI3K-CREB pathway and fusion gene expression, while simultaneously inhibited transcriptional activity regulated by the MEF2D fusion-HDAC axis. CUDC-907 demonstrated remarkable efficacy in patient samples carrying distinct <jats:italic>MEF2D<\/jats:italic> fusion variants in vitro. Furthermore, this compound\u2019s effectiveness and safety were confirmed in both <jats:italic>MH\/NRAS<\/jats:italic>\n            <jats:sup>\n              <jats:italic>G12D<\/jats:italic>\n            <\/jats:sup> BCP-ALL mouse model and <jats:italic>MB<\/jats:italic> patient-derived xenograft (PDX) model, outperforming conventional therapies. These results support the therapeutic potential of dual-pathway inhibition in MEF2D fusion (+) BCP-ALL and suggest CUDC-907 as a promising candidate for precision treatment in fusion-driven leukemias with similar molecular dependencies.<\/jats:p>","DOI":"10.1038\/s41392-025-02310-y","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T23:02:13Z","timestamp":1753225333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL"],"prefix":"10.1038","volume":"10","author":[{"given":"Qing","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiao","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3309-9185","authenticated-orcid":false,"given":"Minghao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2349-208X","authenticated-orcid":false,"given":"Jianfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo-Hui","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qing","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-1284","authenticated-orcid":false,"given":"Sai-Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"2310_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ebiom.2016.04.038","volume":"8","author":"YF Liu","year":"2016","unstructured":"Liu, Y. F. et al. Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. EBioMedicine 8, 173\u2013183 (2016).","journal-title":"EBioMedicine"},{"key":"2310_CR2","doi-asserted-by":"publisher","first-page":"E11711","DOI":"10.1073\/pnas.1814397115","volume":"115","author":"JF Li","year":"2018","unstructured":"Li, J. F. et al. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc. Natl. Acad. Sci. USA115, E11711\u2013E11720 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2310_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","volume":"10","author":"L Pagliaro","year":"2024","unstructured":"Pagliaro, L. et al. Acute lymphoblastic leukaemia. Nat. Rev. Dis. Prim. 10, 41 (2024).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2310_CR4","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui, C. H., Robison, L. L. & Look, A. T. Acute lymphoblastic leukaemia. Lancet 371, 1030\u20131043 (2008).","journal-title":"Lancet"},{"key":"2310_CR5","first-page":"166","volume":"354","author":"P Ching-Hon","year":"2024","unstructured":"Ching-Hon, P. & E, E. W. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166\u2013178 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2310_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3324\/haematol.2017.186320","volume":"104","author":"K Ohki","year":"2019","unstructured":"Ohki, K. et al. Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion. Haematologica 104, 128\u2013137 (2019).","journal-title":"Haematologica"},{"key":"2310_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13331","volume":"7","author":"Z Gu","year":"2016","unstructured":"Gu, Z. et al. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat. Commun. 7, 13331 (2016).","journal-title":"Nat. Commun."},{"key":"2310_CR8","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1200\/JCO.2016.66.5547","volume":"34","author":"K Suzuki","year":"2016","unstructured":"Suzuki, K. et al. MEF2D-BCL9 fusion gene is associated with high-risk acute B-cell precursor lymphoblastic leukemia in adolescents. J. Clin. Oncol. 34, 3451\u20133459 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2310_CR9","first-page":"261","volume":"1870","author":"E Di Giorgio","year":"2018","unstructured":"Di Giorgio, E., Hancock, W. W. & Brancolini, C. MEF2 and the tumorigenic process, hic sunt leones. BBA Rev. Cancer 1870, 261\u2013273 (2018).","journal-title":"BBA Rev. Cancer"},{"key":"2310_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/2643-3230.BCD-19-0080","volume":"1","author":"S Tsuzuki","year":"2020","unstructured":"Tsuzuki, S. et al. Targeting MEF2D-fusion oncogenic transcriptional circuitries in B-cell precursor acute lymphoblastic. Leuk. Blood Cancer Discov. 1, 82\u201395 (2020).","journal-title":"Leuk. Blood Cancer Discov."},{"key":"2310_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1349-7006.2004.tb03240.x","volume":"95","author":"Y Yuki","year":"2004","unstructured":"Yuki, Y. et al. Identification of a novel fusion gene in a pre-B acute lymphoblastic leukemia with t(1;19)(q23;p13). Cancer Sci. 95, 503\u2013507 (2004).","journal-title":"Cancer Sci."},{"key":"2310_CR12","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1182\/blood.2022016241","volume":"140","author":"M Zhang","year":"2022","unstructured":"Zhang, M. et al. Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion. Blood 140, 1390\u20131407 (2022).","journal-title":"Blood"},{"key":"2310_CR13","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1128\/MCB.01415-06","volume":"27","author":"M Haberland","year":"2007","unstructured":"Haberland, M. et al. Regulation of HDAC9 gene expression by MEF2 establishes a negative-feedback loop in the transcriptional circuitry of muscle differentiation. Mol. Cell Biol. 27, 518\u2013525 (2007).","journal-title":"Mol. Cell Biol."},{"key":"2310_CR14","first-page":"1483","volume":"9","author":"VS Gil","year":"2016","unstructured":"Gil, V. S. et al. Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice. Dis. Model Mech. 9, 1483\u20131495 (2016).","journal-title":"Dis. Model Mech."},{"key":"2310_CR15","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.3324\/haematol.2022.281712","volume":"108","author":"I Van Outersterp","year":"2023","unstructured":"Van Outersterp, I. et al. Characterization of a novel MEF2D-BCL9 fusion-positive acute lymphoblastic leukemia cell line. Haematologica 108, 2859\u20132864 (2023).","journal-title":"Haematologica"},{"key":"2310_CR16","doi-asserted-by":"publisher","first-page":"110330","DOI":"10.1016\/j.biopha.2020.110330","volume":"128","author":"N Tange","year":"2020","unstructured":"Tange, N. et al. Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells. Biomed. Pharmacother. 128, 110330 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"2310_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29224-5","volume":"13","author":"IR Leo","year":"2022","unstructured":"Leo, I. R. et al. Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines. Nat. Commun. 13, 1691 (2022).","journal-title":"Nat. Commun."},{"key":"2310_CR18","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s13577-020-00347-5","volume":"33","author":"F Kasai","year":"2020","unstructured":"Kasai, F. et al. Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations. Hum. Cell 33, 868\u2013876 (2020).","journal-title":"Hum. Cell"},{"key":"2310_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307\u2013319 (2013).","journal-title":"Cell"},{"key":"2310_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ccell.2015.02.003","volume":"27","author":"H Geng","year":"2015","unstructured":"Geng, H. et al. Self-enforcing feedback activation between BCL6 and Pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell 27, 409\u2013425 (2015).","journal-title":"Cancer Cell"},{"key":"2310_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","volume":"139","author":"L Srinivasan","year":"2009","unstructured":"Srinivasan, L. et al. PI3 kinase signals BCR-dependent mature B-cell survival. Cell 139, 573\u2013586 (2009).","journal-title":"Cell"},{"key":"2310_CR22","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/leu.2016.9","volume":"30","author":"S K\u00f6hrer","year":"2016","unstructured":"K\u00f6hrer, S. et al. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K\/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia 30, 1246\u20131254 (2016).","journal-title":"Leukemia"},{"key":"2310_CR23","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1182\/blood-2017-10-813576","volume":"131","author":"F Wang","year":"2018","unstructured":"Wang, F. et al. Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia. Blood 131, 2929\u20132942 (2018).","journal-title":"Blood"},{"key":"2310_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri2491","volume":"9","author":"S Herzog","year":"2009","unstructured":"Herzog, S., Reth, M. & Jumaa, H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat. Rev. Immunol. 9, 195\u2013205 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"2310_CR25","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1182\/blood-2015-04-643270","volume":"127","author":"J Herglotz","year":"2016","unstructured":"Herglotz, J. et al. Essential control of early B-cell development by Mef2 transcription factors. Blood 127, 572\u2013581 (2016).","journal-title":"Blood"},{"key":"2310_CR26","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nri3487","volume":"13","author":"RC Rickert","year":"2013","unstructured":"Rickert, R. C. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat. Rev. Immunol. 13, 578\u2013591 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"2310_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.immuni.2008.02.015","volume":"28","author":"T Yasuda","year":"2008","unstructured":"Yasuda, T. et al. Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion. Immunity 28, 499\u2013508 (2008).","journal-title":"Immunity"},{"key":"2310_CR28","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/embor.2009.88","volume":"10","author":"A Nebbioso","year":"2009","unstructured":"Nebbioso, A. et al. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep. 10, 776\u2013782 (2009).","journal-title":"EMBO Rep."},{"key":"2310_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1600-065X.2011.01067.x","volume":"244","author":"RC Rickert","year":"2011","unstructured":"Rickert, R. C., Jellusova, J. & Miletic, A. V. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol. Rev. 244, 115\u2013133 (2011).","journal-title":"Immunol. Rev."},{"key":"2310_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak, A. J. et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103, 689\u2013694 (2004).","journal-title":"Blood"},{"key":"2310_CR31","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1111\/jcmm.16505","volume":"25","author":"P Wang","year":"2021","unstructured":"Wang, P., Zhao, J. & Sun, X. DYRK1A phosphorylates MEF2D and decreases its transcriptional activity. J. Cell Mol. Med. 25, 6082\u20136093 (2021).","journal-title":"J. Cell Mol. Med."},{"key":"2310_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/2643-3249.BCD-20-0078","volume":"1","author":"T Sadras","year":"2020","unstructured":"Sadras, T. & M\u00fcschen, M. MEF2D fusions drive oncogenic pre-BCR signaling in B-ALL. Blood Cancer Discov. 1, 18\u201320 (2020).","journal-title":"Blood Cancer Discov."},{"key":"2310_CR33","first-page":"161","volume":"4","author":"H Zhang","year":"2022","unstructured":"Zhang, H. & Meng, G. A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia. Blood Sci. 4, 161\u2013163 (2022).","journal-title":"Blood Sci."},{"key":"2310_CR34","doi-asserted-by":"publisher","first-page":"108796","DOI":"10.1016\/j.biopha.2019.108796","volume":"114","author":"S Hu","year":"2019","unstructured":"Hu, S. et al. BAFF promotes T cell activation through the BAFF-BAFF-R-PI3K-Akt signaling pathway. Biomed. Pharmacother. 114, 108796 (2019).","journal-title":"Biomed. Pharmacother."},{"key":"2310_CR35","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1158\/0008-5472.CAN-10-0300","volume":"70","author":"R Parameswaran","year":"2010","unstructured":"Parameswaran, R., M\u00fcschen, M., Kim, Y. M., Groffen, J. & Heisterkamp, N. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res. 70, 4346\u20134356 (2010).","journal-title":"Cancer Res."},{"key":"2310_CR36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","volume":"24","author":"FB Vincent","year":"2013","unstructured":"Vincent, F. B., Saulep-Easton, D., Figgett, W. A., Fairfax, K. A. & Mackay, F. The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 24, 203\u2013215 (2013).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2310_CR37","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/1535-7163.MCT-13-1023","volume":"13","author":"R Parameswaran","year":"2014","unstructured":"Parameswaran, R. et al. Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R. Mol. Cancer Ther. 13, 1567\u20131577 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"2310_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.coi.2021.05.011","volume":"71","author":"E McAllister","year":"2021","unstructured":"McAllister, E. & Jellusova, J. BAFF signaling in B cell metabolism. Curr. Opin. Immunol. 71, 69\u201374 (2021).","journal-title":"Curr. Opin. Immunol."},{"key":"2310_CR39","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fonc.2019.00594","volume":"9","author":"E Sevdali","year":"2019","unstructured":"Sevdali, E. et al. BAFF\/APRIL system is functional in B-cell acute lymphoblastic leukemia in a disease subtype manner. Front. Oncol. 9, 594 (2019).","journal-title":"Front. Oncol."},{"key":"2310_CR40","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1172\/JCI60455","volume":"122","author":"S Malinge","year":"2012","unstructured":"Malinge, S. et al. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of down syndrome. J. Clin. Investig. 122, 948\u2013962 (2012).","journal-title":"J. Clin. Investig."},{"key":"2310_CR41","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1182\/blood.2021011247","volume":"138","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. DYRK1a mediates BAFF-induced noncanonical NF-\u03baB activation to promote autoimmunity and B-cell leukemogenesis. Blood 138, 2360\u20132371 (2021).","journal-title":"Blood"},{"key":"2310_CR42","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/blood.2022019094","volume":"142","author":"Q Gao","year":"2023","unstructured":"Gao, Q. et al. The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Blood 142, 711\u2013723 (2023).","journal-title":"Blood"},{"key":"2310_CR43","doi-asserted-by":"publisher","first-page":"e135937","DOI":"10.1172\/JCI135937","volume":"131","author":"RS Bhansali","year":"2021","unstructured":"Bhansali, R. S. et al. DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3. J. Clin. Investig. 131, e135937 (2021).","journal-title":"J. Clin. Investig."},{"key":"2310_CR44","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1084\/jem.20142127","volume":"212","author":"E Jacque","year":"2015","unstructured":"Jacque, E., Schweighoffer, E., Tybulewicz, V. L. J. & Ley, S. C. BAFF activation of the ERK5 MAP kinase pathway regulates B cell survival. J. Exp. Med. 212, 883\u2013892 (2015).","journal-title":"J. Exp. Med."},{"key":"2310_CR45","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.3324\/haematol.2017.172882","volume":"102","author":"Y Oki","year":"2017","unstructured":"Oki, Y. et al. CUDC-907 in relapsed\/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: Results from an expanded phase I trial. Haematologica 102, 1923\u20131930 (2017).","journal-title":"Haematologica"},{"key":"2310_CR46","first-page":"1262","volume":"106","author":"X Li","year":"2021","unstructured":"Li, X. et al. The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Haematologica 106, 1262\u20131277 (2021).","journal-title":"Haematologica"},{"key":"2310_CR47","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/jcmm.13935","volume":"23","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL. J. Cell Mol. Med. 23, 340\u2013348 (2019).","journal-title":"J. Cell Mol. Med."},{"key":"2310_CR48","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S1470-2045(15)00584-7","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes, A. et al. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol. 17, 622\u2013631 (2016).","journal-title":"Lancet Oncol."},{"key":"2310_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","volume":"129","author":"SK Tasian","year":"2017","unstructured":"Tasian, S. K. et al. Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 129, 177\u2013187 (2017).","journal-title":"Blood"},{"key":"2310_CR50","doi-asserted-by":"publisher","first-page":"5044","DOI":"10.1158\/1078-0432.CCR-17-1043","volume":"23","author":"S Kotian","year":"2017","unstructured":"Kotian, S. et al. Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases. Clin. Cancer Res. 23, 5044\u20135054 (2017).","journal-title":"Clin. Cancer Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02310-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02310-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02310-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:36:37Z","timestamp":1757241397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02310-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2310"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02310-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}